Journal of Southern Medical University ›› 2016, Vol. 36 ›› Issue (01): 56-.
Previous Articles Next Articles
Online:
Published:
Abstract: Objective To test the effect of the c-Met inhibitor cabozantinib in inhibiting infections by Listeria monocytogenes (LM)in mice. Methods C57BL/6 mice at 6 weeks of age were subjected to intraperitoneal injection of LM and randomized into 4groups for treatment with intraperitoneal injection of PBS, intragastric administration of cabozantinib (20 μg/g), intraperitonealinjection of ampicillin (Amp, 20 μg/g), or cabozantinib plus Amp. The survival curves were drawn for each group, and thenumber of bacteria in the blood and brain tissues was determined; serum IL-10 level and NF-κB p65 level in the cerebrospinalfluid (CSF) were assayed, and Evans Blue (EB) content and pathological changes in brain were examined. Results Comparedwith PBS-treated mice, the mice treated with cabozantinib showed a significantly higher survival rate, lower bacterial counts inthe blood and brain (P<0.05 or 0.001), lower IL-10 (P<0.05) and NF-κB p65 levels (P<0.01), lower brain EB content (P<0.001), andmilder pathological changes in the brain. The blood and brain bacterial counts (P<0.001), IL-10 (P<0.01) and NF-κB p65 levels(P<0.001), and brain EB content (P<0.001) were all significantly lower in mice treated with the combination of drugs than inmice treated with cabozantinib alone. Conclusion Cabozantinib can inhibit LM infection in mice and has important values indeveloping new anti-intracellular infection drug.
0 / / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.j-smu.com/EN/
https://www.j-smu.com/EN/Y2016/V36/I01/56